Genentech discloses safety concerns over Avastin.
Mark
M
Ratner
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003110:Colonic Neoplasms / Q000188:drug therapy*; D003257:Consumer Product Safety; D030881:Disclosure; D017277:Drug Approval; D006801:Humans; D019221:Mandatory Reporting; D018570:Risk Assessment; D012307:Risk Factors; D013927:Thrombosis / Q000139:chemically induced*; D014481:United States
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab